ACTC is a confirmed buy

Do charts matter when shorts are in control? The bid at 1.70 got chewed up fast at end of day. Not much volume overall though

All I know is short scabs will see there day soon enough. To the moon Louis to the moon

Everyone just set GTC orders at $5 that ways your shares can't be borrowed. Also shares in a brokerage account can only be borrowed unless a GTC order is in place. Cash accounts can't be borrowed. This is all what I have been told.

http://www.myfoxorlando.com/story/20587134/3d-tool-helping-to-detect-skin-cancer

$150 per visit. Not bad, there are 8 locations withing 100 miles of me. I think this is going to be a big thing, sooner then later if u ask me

Who is unloading all these shares?

+.02 is a lot better then -.15 to moon tomorrow we go

Positive earnings are predicted for earnings next week. $1+ next week

So from the looks of the chart, I say we are still on ride up.

This seller is a damn joke. All day since it hit 1.64

DD from the $heff http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83471578

DCTH WEDBUSH has a Outperform on Delcath Systems and $10 PT

DARA BioSciences (DARA)?-?Meeting with David Benharris (VP Sales & Marketing).?I came away from my meeting with David Benharris confident that the turnaround at DARA Bio continues. This is a company that had a rocky 2011, but made?significant changes?in both management and focus early in 2012. I turned?bullish on DARA?late last year after the company announced it had launched both Bionect and Soltamox, and was preparing to launch yet another product in Gelclair in 2013. Soltamox is the company?s flagship product, an oral liquid formulation of the breast cancer drug tamoxifen. Current?clinical practice guidelines?from the American Society of Clinical Oncology recommend women with estrogen receptor positive (ER+) breast cancer stay on tamoxifen for five years. However, data from a new?study published in The Lancet?and presented at the San?Antonio Breast Cancer Symposium?in December 2012 showed that women taking tamoxifen for 10 years (ATLAS, n=12894) cut their risk of mortality by 29% when compared to women stopping treatment after five years. This is clearly good news for DARA and Soltamox. Soltamox is an oral liquid?bioequivalent?formulation to tamoxifen. DARA has conducted market research showing that up to 10% of women on tamoxifen prefer an oral liquid formulation due to dysphagia, perhaps the result of oral mucositis. Roughly 225,000 women take tamoxifen yearly, so just 5% market share for DARA?s Soltamox would be significant revenues for the small company. Additionally, the company is expecting to hear back from the U.S. FDA on the orphan drug application on KRN5500 in March or April 2013. I believe orphan drug designation for KRN5500 would be?huge for DARA. Finally, I was pleased to see the company?secure enough cash?to fund operations into 2014. DARA is set up to perform well this year.

I'm not too deep in PATH but would like for them to get approved this time. I'm deep in IPXL for the upcoming PDUFA

I would like to think so.

Shit ton of insider buys, always a good thing

We have a gap to fill from 2.27-2.50 lets fill it up.

No details on who or why. We may or may not find out also. I wasn't told. It was what I read. Check the hashtag on twitter

Was told they were pre arranged sales at .50

$1.50 PT from Jefferies with a BUY rating

$1.50 PT from Jefferies with a BUY rating

Jefferies inits $APPA with a buy rating

This MM is scum. Look at all the buys at 1.66 and not a tick higher. Then 1 sell and back down it goes. What a joke

6 million shares purchased at $2.25 2 form 4's filed today

I believe this dump at the end of the day was planned. All the big buys were rebalancing I believe since it was last day of quarter.

I'm holding $ANX as well. There was a big conference todayToday "Sickle Cell Disease Therapeutics Conference" could be news soon. Plus phase 3 initiation

CUR did an offering after a good run. But CPRX is running up to data. No need for an offering. There is a lot of Scab shorts that need to cover still. Rumor has it close to 3$ a share. After 2.28 resistance next is 2.80

Thank for the compliment. Bought in at .87 20000 shares, cashed out today at 1.09 for a nice 4400 profit since Thursday last week?

They have plenty of cash. 209000 was obviously an idiot selling early. This is going even higher. Paint the tape as its called. Which is why the price went right back up after a buy.

Next resistance is $1.12 first was $0.99 lets make it happen.

Wow 209000 sell after hours, wth

Check out NASDAQ.com trades between 16:40 and 16:41 in order go. 2200 shares bought. Market high of $8.20 next is a sale of 150 shares for a price of $6.90 I reported this to the SEC TCR SubmittedSuccessfully - Reference Number: TCR1343355208436
This is fraudulent stuff, this needs to be looked into.

Do you see them trades. Total bullshit. 100 shares drop it 45 cents. No way in hell. They are short selling the shit out of this

$10 Aug. Calls getting chewed up. Get them while they are cheap.

Ours is about 7g. Plus plane tickets.. so I got alot of money to make. I just looked at the Aug. Options for Amrn and they are expensive already. I think we need alot more volume and the pps will explode

Good luck to you also. I gotta pay this Disneyworld trip off. So I want to see 2+ on these calls

Well we are at .20 and at 7.20 so by 10.20 who knows. Hopefully everything goes.as planned. .

I bought my options first thing this morning. I kept placing .10 and .15 orders and never got filled. Then did a market order and got filled at .20 later in the day I saw they dropped down to .15 i was pissed. I think as we keep climbing up. Fingers crossed

Yes. I saw the big candles at opening. This has a small float, which means big ups, and can mean big downs also. Im hoping for nice run up next week. Them $10 Aug calls are looking better and better. They had some buying today. I say 11.50-12+ before or after approval.

From what I hear, MM's can keep it down or up so certain clients can profit. Imagine that, sounds fair from a small retailers view.